Study of regn21353 with or without nezastomig for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests two new drugs, regn21353 and nezastomig, alone or together, in men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if these drugs can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man with prostate cancer that has spread and is no longer controlled by hormone therapy.
- You have already tried at least two approved treatments for advanced prostate cancer, including a drug like abiraterone, enzalutamide, apalutamide, or darolutamide.
- Your cancer has gotten worse within the last 6 months before the study starts.
- You are willing to provide a tumor sample (either from a past biopsy or a new one).
- You are generally healthy and able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This trial tests a new combination of two drugs for men with advanced prostate cancer that has stopped responding to standard hormone therapy or chemotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial tests a combination of two drugs (REGN5678 and cemiplimab) for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to see if this new combination can help shrink the cancer or slow its growth.
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.